Hepatitis C Virus (HCV)

CAS No.	Product Name	Inquiry
1149348-10-6	FGI-106-tetrahydrochloride FGI-106 tetrahydrochloride is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI- 106 tetrahydrochloride is active against Ebola, Rift Valley and Dengue Fever viruses with EC50s of 100 nM, 800 nM and 400-900 nM, respectively. FGI-106 tetrahydrochloride also inhibits non-hemorrhagic fever viruses HCV and HIV-1 with EC50s of 200 nM and 150 nM, respectively.
1169766-14-6	Morin-3-O-β-D-glucopyranoside Morin 3-O-β-D-glucopyranoside is a natural flavonoid with antifungal, anticancer and antioxidant activities. Morin 3-O-β-D-glucopyranoside inhibits reverse transcriptase, protein-tyrosine kinase and xanthine oxidase, and also shows anti-HIV, antiarteriosclerotic, and superoxide scavenging activities.
117824-04-1	Dehydrojuncusol Dehydrojuncusol, a potent HCV inhibitor, targets HCV NS5A and is able to inhibit RNA replication of replicons harboring resistance mutations to anti-NS5A direct-acting antivirals. Dehydrojuncusol significantly inhibits HCV infection when added after virus inoculation of HCV genotype 2a (EC50=1.35 µM).
119567-79-2	Taribavirin Taribavirin is an orally active inosine monophosphate dehydrogenase inhibitor that is active against a variety of viruses, particularly hepatitis C virus and influenza virus. It is a ribavirin prodrug designed to cluster in the liver and target hepatitis C virus-infected liver cells while minimizing distribution in red blood cells and the development of hemolytic anemia.
1200133-34-1	VCH-916 VCH-916 is a novel allosteric inhibitor of HCV NS5B polymerase. The RNA-dependent RNA polymerase (NS5B) of HCV is one of the attractive validated targets for development of new drugs to block HCV infection. VCH-916 is currently being evaluated for safety/tolerability, pharmacokinetics and anti-viral efficacy in chronically infected HCV patient.
1206524-86-8	MK-5172 potassium salt In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a. In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose.
121104-96-9	6-O-butyl castanospermine Celgosivir, an effective α-glucosidase I inhibitor, has been found to be related to viral maturation and is still under Phase I/II trial against Dengue. IC50: 16 and 47 umol/L (through plaque assay and a cytopathic assay).
1231747-17-3	PSI-352938 PSI-352938 is an inhibitor of hepatitis C virus (HCV) nucleotide.
1234490-83-5	INX 08189 BMS-986094 (INX-08189) is a potent inhibitor of hepatitis C virus (HCV) replication, with an EC50 of 35 nM at 24 h in Huh-7 cells. BMS-986094 is a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine. BMS-986094 can be used for the research of chronic HCV infection.
1241946-89-3	Simeprevir sodium salt Simeprevir is an orally bioavailable inhibitor of the hepatitis C virus (HCV) NS3/4A protease. It has been approved in combination with peginterferon-alfa and ribavirin for the treatment of HCV and HBV infections.
1252679-52-9	ITX-5061 HCl This active molecular is a scavenger receptor B1 antagonist under the development by iTherX Pharmaceuticals for the treatment of Hepatitis C. ITX-5061 shows a special mechanism of action that prevents the hepatitis C virus from entering liver cells. Preclinical studies have shown that ITX-5061 can prevent virus binding/fusion and cell to cell spread. In Jan 2015, Phase-II clinical trials in Hepatitis C in USA was on-going.
1256388-51-8	Ledipasvir Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.
1256490-42-2	Sofosbuvir metabolite GS331007-[13C,d3] An isotope labelled metabolite of Sofosbuvir. Sofosbuviis a medication used for the treatment of hepatitis C.
1256751-11-7	Boceprevir-[d9] Boceprevir-[d9] is a stable isotopic labelled compound of Boceprevir. Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection.
1258226-87-7	Ombitasvir Ombitasvir, a NS5A inhibitor, could be effective in the treatment of HCV as an antiviral agent. IC50: 14 pM and 5 pM (EC50) for genotype 1a-H77 and 1b-Con1 respectively.
1312547-19-5	Samatasvir Samatasvir is a potent HCV replication NS5A inhibitor that is effective and selective against infectious HCV and replicons with EC50s falling within a tight range of 2 to 24 pM for genotype 1-5 replicons.
1314795-11-3	Radalbuvir Radalbuvir is a Hepatitis C virus NS 5 protein inhibitor for the treatment of hepatitis C virus (HCV) infection developed by Gilead Sciences. In 2014, Gilead completed a phase II trial for Hepatitis C in USA.
131707-25-0	Umifenovir Arbidol is an antiviral agent using for the treatment of influenza infection in Russia and China. It inhibits membrane fusion and prevents contact between the virus and target host cells. Fusion between the viral capsid and the cell membrane of the target cell is inhibited and this prevents viral entry to the target cell. Although some Russian studies have shown it to be effective, it is not approved for use in Western countries.
1331942-30-3	GSK5852 GSK5852 (GSK2485852) is an HCV NS5B polymerase inhibitor, with an IC50 value of 50 nM. GSK5852 displays antiviral activity and inhibits HCV with EC50s of 3.0 nM (genotype 1a, GT1a) and 1.7 nM (GT1b), respectively.
1333126-31-0	Azvudine hydrochloride Azvudine hydrochloride is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV. Azvudine hydrochloride inhibits NRTI-resistant viral strains.

※ Please kindly note that our services are for research use only.